Allocation Concealment and Blinding Guard Different Parts of a Trial

Allocation concealment and blinding solve different problems at different times. Concealment protects the entrance to a randomized trial, before the assignment is revealed. Blinding protects what happens after entry. A trial report that says only “double blind” has not told you whether allocation was secure.

Key points#

• Random sequence generation creates an unpredictable order of assignments.
• Allocation concealment keeps that order unavailable to people deciding who enters the trial.
• Blinding keeps selected participants, care teams, assessors, or analysts unaware of the assigned intervention after randomization.
• A trial can be openly conducted and still have excellent concealment, or it can be blinded after a flawed assignment process.
• CONSORT 2025 asks authors to report the concealment mechanism and identify exactly who was blinded.

Three questions, not one#

Randomization is often described as though drawing assignments were a single act. In practice, a trustworthy process has at least three distinct parts.

First, someone generates the sequence. A computer may produce a random order, perhaps with blocks or stratification. This answers whether the list itself was unpredictable.

Second, the sequence is implemented. The clinician or coordinator enrolling the next participant must not know what the list will assign. This is allocation concealment.

Third, after assignment, the trial may hide the intervention from participants, clinicians, outcome assessors, data analysts, or some combination. This is blinding, also called masking. Each part blocks a different route by which expectations or preferences could distort the comparison. Reporting one does not establish the others.

The bias concealment prevents#

Eligibility decisions frequently require judgment. A patient may be near a severity cutoff, have an uncertain diagnosis, or arrive when several eligible people could be approached, and if an enrolling clinician knows the next assignment is the intervention they favor, they may consciously or unconsciously work harder to include a promising participant. If the next assignment is control, they may wait for someone else.

That small steering action changes who enters each arm. The nominally randomized groups can then differ in prognosis before treatment begins, and later statistical adjustment cannot fully restore the protection that was lost because the unmeasured reasons for enrollment may matter as much as the measured ones.

Proper concealment makes the enrollment decision irreversible before the assignment becomes visible. Common methods include a secure central web or telephone system and a pharmacy-controlled process. Sequentially numbered, opaque, sealed envelopes can work, but only with safeguards against holding them to light, opening them early, replacing them, or selecting envelopes out of order. Saying “sealed envelopes were used” is not enough detail for you to judge the method.

The biases blinding prevents#

Once the assignment is known, several other pathways open.

Participants who believe they received the new intervention may report symptoms differently, adhere more closely, or seek other care differently. Clinicians may provide extra attention, alter co-interventions, adjust thresholds for rescue treatment, or investigate adverse events with different intensity, and outcome assessors may classify a borderline event in the direction they expect. Analysts can make apparently defensible choices that favor a preferred result if group identities are visible during data cleaning and modeling.

Blinding can interrupt some of these pathways, but the relevant people depend on the outcome; blinding a laboratory assessor matters little for an automated value if the device is reliable. Blinding a committee judging a subjective composite endpoint may matter greatly. Participant blinding can be central for pain or quality-of-life outcomes, yet less important for all-cause mortality.

This is why labels such as “single blind” and “double blind” are too vague. They do not say who lacked the information or how the blind was maintained. CONSORT 2025 instead asks authors to name the blinded groups and describe the procedures.

Four trial designs that separate the concepts#

Secure randomization, open treatment#

A surgical trial can use a central randomization service after eligibility and consent are locked. Surgeons and patients then know which procedure occurred. Allocation was concealed even though treatment was open-label.

Secure randomization, blinded outcome review#

A pragmatic medication trial may let patients and clinicians know the treatment but send suspected events to an independent committee that sees redacted records; concealment protects baseline comparability, and blinded adjudication protects event classification. Behavior and symptom reporting remain open to influence.

Weak concealment, convincing placebo#

Suppose a coordinator can predict assignments because a fixed alternating sequence is used. Once assigned, participants receive identical tablets and appear well blinded. The trial can still be biased because selection occurred before the tablets were dispensed.

Secure concealment, broken blind#

A pharmacy may randomize and conceal assignment perfectly, but a recognizable side effect reveals the intervention during follow-up. Baseline comparability remains protected. Later care and reporting may still differ because the blind did not hold.

These four show why you can never let concealment and blinding stand in for each other in a risk-of-bias assessment.

What the evidence says about inadequate concealment#

Empirical comparisons have repeatedly found that trials with inadequate or unclear concealment can report larger treatment effects than trials with secure methods. The exact amount varies across datasets and outcomes, so it should not be treated as a universal correction factor. The direction is clinically plausible: if enrollment can be steered, randomization no longer guarantees exchangeable groups.

An “unclear” rating is also not proof that the process was poor. It can mean only that the paper failed to describe it. That distinction matters for judging conduct, but not for what you can actually verify. Incomplete reporting leaves uncertainty, which is why modern reporting guidance requests the implementation details.

How to appraise concealment in a paper#

Look for a concrete chain of custody:

1. Who generated the random sequence?
2. Who enrolled participants?
3. Who assigned the intervention?
4. Could either of the latter two access or predict the next assignment?
5. What mechanism withheld the sequence until eligibility and consent were complete?
6. If blocks were used, could small fixed block sizes make later assignments predictable?
7. Were envelopes truly sequential, opaque, tamper-evident, and opened only after enrollment?

Then perform a separate blinding audit:

• Which participants, care providers, data collectors, outcome assessors, and analysts were blinded?
• Could side effects, laboratory changes, or visible procedures reveal assignment?
• Was the primary outcome objective, self-reported, or judgment-dependent?
• Were co-interventions and follow-up intensity similar?
• If blinding was impossible, did the trial use blinded adjudication or other safeguards?

The answers should match the trial's actual risk. An unblinded outcome is not automatically biased, and a blinded trial is not automatically trustworthy. Bias depends on what knowledge could change and whether the design blocked that route.